Sign In
Buy PPCB
$1.77
-0.0400 (-2.21%)
At Close: Jun 02, 2026
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
08:45am, Thursday, 15'th Jan 2026
This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma's pancreatic proenzyme formulation known as PRP.
Propanc Biopharma Provides Shareholder Update
08:45am, Tuesday, 13'th Jan 2026
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
07:00am, Monday, 22'nd Dec 2025
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
08:45am, Thursday, 04'th Dec 2025
MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
08:45am, Monday, 01'st Dec 2025
These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis
Propanc Biopharma (OTCMKTS:PPCB) Shares Down 3.7% – Should You Sell?
02:16am, Friday, 21'st Nov 2025
Shares of Propanc Biopharma Inc (OTCMKTS:PPCB - Get Free Report) dropped 3.7% on Thursday. The company traded as low as $0.7898 and last traded at $0.8277. Approximately 46,204 shares were traded duri
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
08:45am, Monday, 17'th Nov 2025
MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurre
MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients
We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
08:45am, Tuesday, 07'th Oct 2025
Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
08:45am, Wednesday, 17'th Sep 2025
MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
09:00am, Tuesday, 02'nd Sep 2025
Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.
Propanc Biopharma Provides Shareholder Update
07:30am, Monday, 25'th Aug 2025
Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
08:30am, Tuesday, 19'th Aug 2025
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
12:25am, Saturday, 16'th Aug 2025
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma
